WO2008143254A1 - ＰＰＡＲδアゴニスト含有医薬 - Google Patents

ＰＰＡＲδアゴニスト含有医薬 Download PDF

Info

Publication number
WO2008143254A1
WO2008143254A1 PCT/JP2008/059236 JP2008059236W WO2008143254A1 WO 2008143254 A1 WO2008143254 A1 WO 2008143254A1 JP 2008059236 W JP2008059236 W JP 2008059236W WO 2008143254 A1 WO2008143254 A1 WO 2008143254A1
Authority
WO
WIPO (PCT)
Prior art keywords
epithelial cells
meibomian gland
isopropyl
agent
methylphenoxy
Prior art date
Application number
PCT/JP2008/059236
Other languages
English (en)
French (fr)
Inventor
Yoshikuni Nakamura
Ikuko Hanano
Jun Inoue
Original Assignee
Senju Pharmaceutical Co., Ltd.
Nippon Chemiphar Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/451,564 priority Critical patent/US8802705B2/en
Application filed by Senju Pharmaceutical Co., Ltd., Nippon Chemiphar Co., Ltd. filed Critical Senju Pharmaceutical Co., Ltd.
Priority to BRPI0811612-1A2A priority patent/BRPI0811612A2/pt
Priority to PL08764395T priority patent/PL2151438T3/pl
Priority to KR1020097026251A priority patent/KR101508020B1/ko
Priority to CN200880025498XA priority patent/CN101801941B/zh
Priority to DK08764395.3T priority patent/DK2151438T3/da
Priority to EP08764395A priority patent/EP2151438B1/en
Priority to ES08764395T priority patent/ES2393424T3/es
Priority to CA2687957A priority patent/CA2687957C/en
Priority to JP2009515245A priority patent/JP5247686B2/ja
Priority to MX2009012600A priority patent/MX2009012600A/es
Publication of WO2008143254A1 publication Critical patent/WO2008143254A1/ja
Priority to US14/317,145 priority patent/US9463185B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

　マイボーム腺上皮細胞および角膜上皮細胞の増殖促進剤を提供すること、並びに、マイボーム腺機能不全・ドライアイ等の眼疾患の治療剤を提供すること。 　［３－［２－［４－イソプロピル－２－（４－トリフルオロメチル）フェニル－５－チアゾリル］エチル］－５－メチル－１，２－ベンズイソキサゾール－６－イル］オキシ酢酸、［４－［３－［２－（４－トリフルオロメチル）フェニル－４－イソプロピル－５－チアゾリル］プロピオニル］－２－メチルフェノキシ］酢酸もしくは［４－［３－［２－（２－ヒドロキシ－４－クロロフェニル）－５－イソプロピル－４－オキサゾリル］プロピオニル］－２－メチルフェノキシ］酢酸またはその薬理学的に許容される塩を有効成分として含有する製剤を、マイボーム腺上皮細胞または角膜上皮細胞の増殖促進剤、並びに、マイボーム腺機能不全・ドライアイ等の眼疾患の治療剤として使用する。
PCT/JP2008/059236 2007-05-21 2008-05-20 ＰＰＡＲδアゴニスト含有医薬 WO2008143254A1 (ja)

Priority Applications (12)

Application Number Priority Date Filing Date Title
DK08764395.3T DK2151438T3 (da) 2007-05-21 2008-05-20 Lægemiddel indeholdende PPAR-Deltaagonist
BRPI0811612-1A2A BRPI0811612A2 (pt) 2007-05-21 2008-05-20 Composições farmacêuticas que contêm agonista ppardelta
PL08764395T PL2151438T3 (pl) 2007-05-21 2008-05-20 Kompozycja farmaceutyczna zawierająca agonistę PPAR-DELTA
KR1020097026251A KR101508020B1 (ko) 2007-05-21 2008-05-20 Ｐｐａｒδ 아고니스트 함유 의약
CN200880025498XA CN101801941B (zh) 2007-05-21 2008-05-20 含有ppar△激动剂的药物
US12/451,564 US8802705B2 (en) 2007-05-21 2008-05-20 Pharmaceutical containing PPAR delta agonist
EP08764395A EP2151438B1 (en) 2007-05-21 2008-05-20 Pharmaceutical containing ppar-delta agonist
JP2009515245A JP5247686B2 (ja) 2007-05-21 2008-05-20 ＰＰＡＲδアゴニスト含有医薬
CA2687957A CA2687957C (en) 2007-05-21 2008-05-20 Pharmaceutical containing ppar.delta. agonist
ES08764395T ES2393424T3 (es) 2007-05-21 2008-05-20 Agente farmacéutico que contiene un agonista de PPAR-delta
MX2009012600A MX2009012600A (es) 2007-05-21 2008-05-20 Farmaceutico que contiene el agonista ppar alfa.
US14/317,145 US9463185B2 (en) 2007-05-21 2014-06-27 Pharmaceutical containing PPAR-delta agonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-134183 2007-05-21
JP2007134183 2007-05-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/451,564 A-371-Of-International US8802705B2 (en) 2007-05-21 2008-05-20 Pharmaceutical containing PPAR delta agonist
US14/317,145 Division US9463185B2 (en) 2007-05-21 2014-06-27 Pharmaceutical containing PPAR-delta agonist

Publications (1)

Publication Number Publication Date
WO2008143254A1 true WO2008143254A1 (ja) 2008-11-27

Family

ID=40031950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/059236 WO2008143254A1 (ja) 2007-05-21 2008-05-20 ＰＰＡＲδアゴニスト含有医薬

Country Status (14)

Country Link
US (2) US8802705B2 (ja)
EP (1) EP2151438B1 (ja)
JP (1) JP5247686B2 (ja)
KR (1) KR101508020B1 (ja)
CN (1) CN101801941B (ja)
BR (1) BRPI0811612A2 (ja)
CA (1) CA2687957C (ja)
DK (1) DK2151438T3 (ja)
ES (1) ES2393424T3 (ja)
MX (1) MX2009012600A (ja)
PL (1) PL2151438T3 (ja)
PT (1) PT2151438E (ja)
RU (1) RU2449789C2 (ja)
WO (1) WO2008143254A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014119643A1 (ja) 2013-01-31 2014-08-07 千寿製薬株式会社 澄明な水性液剤
WO2014119642A1 (ja) 2013-01-31 2014-08-07 千寿製薬株式会社 安定な水性液剤
WO2016199871A1 (ja) * 2015-06-09 2016-12-15 千寿製薬株式会社 神経麻痺性角膜症の治療薬
WO2017195875A1 (ja) * 2016-05-12 2017-11-16 日本ケミファ株式会社 創傷治療剤

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US20090043365A1 (en) 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US7981146B2 (en) 2006-05-15 2011-07-19 Tearscience Inc. Inner eyelid treatment for treating meibomian gland dysfunction
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US20070016256A1 (en) 2005-07-18 2007-01-18 Korb Donald R Method and apparatus for treating gland dysfunction
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US8007524B2 (en) 2006-05-15 2011-08-30 Tearscience, Inc. Heat treatment and heat loss reduction for treating meibomian gland dysfunction
US7981147B2 (en) 2006-05-15 2011-07-19 Tearscience, Inc. Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7976573B2 (en) 2006-05-15 2011-07-12 Tearscience, Inc. Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8128673B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
WO2008027069A1 (en) 2006-08-21 2008-03-06 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid
USD638128S1 (en) 2009-10-06 2011-05-17 Tearscience, Inc. Ocular device design
WO2014031857A2 (en) 2012-08-22 2014-02-27 Tearscience, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
ES2942724T3 (es) 2013-04-30 2023-06-06 Alcon Inc Sistemas para el tratamiento de enfermedades del ojo
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth
CN110229886A (zh) * 2019-07-05 2019-09-13 杭州笙源生物科技有限公司 一种PPARγ用于诊断肝衰竭的新用途及试剂盒及试剂盒用于诊断肝衰竭的应用
CN112569179B (zh) * 2020-12-25 2022-12-27 上海交通大学医学院附属第九人民医院 一种可注射水凝胶体系及其制备方法

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09207959A (ja) 1995-06-26 1997-08-12 Taisho Pharmaceut Co Ltd 液剤充填容器
WO1998025598A2 (en) 1996-12-11 1998-06-18 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumour cell growth
JP2001039976A (ja) 1999-05-24 2001-02-13 Sankyo Co Ltd 縮合複素環化合物の塩酸塩
WO2002069994A2 (en) 2001-03-07 2002-09-12 Novo Nordisk A/S Combined use of derivatives of glp-1 analogs and ppar ligands
WO2002076177A2 (en) 2001-03-23 2002-10-03 Bethesda Pharmaceuticals, Inc. Design and synthesis of optimized ligands for ppar
JP2002539166A (ja) * 1999-03-17 2002-11-19 ザ スキーペンズ アイ リサーチ インスティテュート インコーポレイテッド 局所適用したアンドロゲン又はＴＧＦ−βを用いた乾性角結膜炎における眼の治療
WO2003016291A1 (fr) 2001-08-10 2003-02-27 Nippon Chemiphar Co., Ltd. Activateur du recepteur $g(d) sensible au proliferateur de peroxysome
WO2003033493A1 (fr) 2001-10-12 2003-04-24 Nippon Chemiphar Co.,Ltd. Activateur du recepteur $g(d) active par le proliferateur de peroxisome
WO2004006826A1 (ja) 2002-07-16 2004-01-22 Senju Pharmaceutical Co., Ltd. 薬液容器及びその製造方法
JP2004175749A (ja) * 2002-11-28 2004-06-24 Senju Pharmaceut Co Ltd ドライアイおよびドライアイを伴う疾病の治療剤
JP2005008570A (ja) 2003-06-19 2005-01-13 Santen Pharmaceut Co Ltd 角膜疾患治療剤
WO2005039574A1 (ja) 2003-10-24 2005-05-06 Santen Pharmaceutical Co., Ltd. 角結膜障害の治療剤
JP2006176499A (ja) * 2004-11-25 2006-07-06 Nippon Seibutsu Seizai:Kk 眼疾患治療剤
WO2007061094A1 (ja) * 2005-11-28 2007-05-31 Senju Pharmaceutical Co., Ltd. Ｐｐａｒアゴニスト含有医薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688765A (en) * 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
TWI284533B (en) 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
WO2002013812A1 (en) * 2000-08-17 2002-02-21 Pershadsingh Harrihar A Methods for treating inflammatory diseases
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
AR056682A1 (es) * 2005-07-29 2007-10-17 Kalypsys Inc COMPUESTOS MULTICíCLICOS DERIVADOS DE LA SULFONAMIDA COMO INHIBIDORES DE LA HISTONA DESACETILASA Y COMPOSICIoN FARMACÉUTICA

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09207959A (ja) 1995-06-26 1997-08-12 Taisho Pharmaceut Co Ltd 液剤充填容器
WO1998025598A2 (en) 1996-12-11 1998-06-18 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumour cell growth
JP2002539166A (ja) * 1999-03-17 2002-11-19 ザ スキーペンズ アイ リサーチ インスティテュート インコーポレイテッド 局所適用したアンドロゲン又はＴＧＦ−βを用いた乾性角結膜炎における眼の治療
JP2001039976A (ja) 1999-05-24 2001-02-13 Sankyo Co Ltd 縮合複素環化合物の塩酸塩
WO2002069994A2 (en) 2001-03-07 2002-09-12 Novo Nordisk A/S Combined use of derivatives of glp-1 analogs and ppar ligands
WO2002076177A2 (en) 2001-03-23 2002-10-03 Bethesda Pharmaceuticals, Inc. Design and synthesis of optimized ligands for ppar
WO2003016291A1 (fr) 2001-08-10 2003-02-27 Nippon Chemiphar Co., Ltd. Activateur du recepteur $g(d) sensible au proliferateur de peroxysome
WO2003033493A1 (fr) 2001-10-12 2003-04-24 Nippon Chemiphar Co.,Ltd. Activateur du recepteur $g(d) active par le proliferateur de peroxisome
WO2004006826A1 (ja) 2002-07-16 2004-01-22 Senju Pharmaceutical Co., Ltd. 薬液容器及びその製造方法
JP2004175749A (ja) * 2002-11-28 2004-06-24 Senju Pharmaceut Co Ltd ドライアイおよびドライアイを伴う疾病の治療剤
JP2005008570A (ja) 2003-06-19 2005-01-13 Santen Pharmaceut Co Ltd 角膜疾患治療剤
WO2005039574A1 (ja) 2003-10-24 2005-05-06 Santen Pharmaceutical Co., Ltd. 角結膜障害の治療剤
JP2006176499A (ja) * 2004-11-25 2006-07-06 Nippon Seibutsu Seizai:Kk 眼疾患治療剤
WO2007061094A1 (ja) * 2005-11-28 2007-05-31 Senju Pharmaceutical Co., Ltd. Ｐｐａｒアゴニスト含有医薬

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AM J CLIN DERMATOL, vol. 4, no. 8, 2003, pages 523 - 530
BEAUREGARD C. ET AL.: "Peroxisome Proliferator-Activated Receptor Agonists Inhibit Interleukin-1beta-Mediated Nitric Oxide Production in Cultured Lacrimal Gland Acinar Cells", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, vol. 19, no. 6, 2003, pages 579 - 587, XP008127428 *
BONAZZI A. ET AL., J. BIOL. CHEM., vol. 275, no. 4, 2000, pages 2837 - 2844
J BIOL CHEM, vol. 275, 2000, pages 2837
J MED CHEM, vol. 43, 2000, pages 527 - 550
J.M. LEHMANN ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 22, 1995, pages 12953 - 12956
MOLECULAR GENETIC AND METABOLISM, vol. 74, 2001, pages 362 - 369
See also references of EP2151438A4 *
T.M. WILLSON ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 4, 2000, pages 528 - 550

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014119643A1 (ja) 2013-01-31 2014-08-07 千寿製薬株式会社 澄明な水性液剤
WO2014119642A1 (ja) 2013-01-31 2014-08-07 千寿製薬株式会社 安定な水性液剤
JP5753958B2 (ja) * 2013-01-31 2015-07-22 千寿製薬株式会社 澄明な水性液剤
JP5753957B2 (ja) * 2013-01-31 2015-07-22 千寿製薬株式会社 安定な水性液剤
JPWO2014119642A1 (ja) * 2013-01-31 2017-01-26 千寿製薬株式会社 安定な水性液剤
US9968679B2 (en) 2013-01-31 2018-05-15 Senju Pharmaceutical Co., Ltd. Clear aqueous solution
RU2662067C2 (ru) * 2013-01-31 2018-07-23 Сэндзю Фармасьютикал Ко., Лтд. Прозрачный водный раствор
US10709786B2 (en) 2013-01-31 2020-07-14 Senju Pharmaceutical Co., Ltd. Clear aqueous solution
WO2016199871A1 (ja) * 2015-06-09 2016-12-15 千寿製薬株式会社 神経麻痺性角膜症の治療薬
WO2017195875A1 (ja) * 2016-05-12 2017-11-16 日本ケミファ株式会社 創傷治療剤

Also Published As

Publication number Publication date
KR101508020B1 (ko) 2015-04-06
JPWO2008143254A1 (ja) 2010-08-12
US8802705B2 (en) 2014-08-12
CA2687957A1 (en) 2008-11-27
PL2151438T3 (pl) 2013-03-29
US20140343109A1 (en) 2014-11-20
MX2009012600A (es) 2010-03-15
PT2151438E (pt) 2012-11-15
US9463185B2 (en) 2016-10-11
US20120270910A2 (en) 2012-10-25
BRPI0811612A2 (pt) 2014-11-11
US20100190833A1 (en) 2010-07-29
EP2151438B1 (en) 2012-10-31
KR20100037038A (ko) 2010-04-08
EP2151438A1 (en) 2010-02-10
JP5247686B2 (ja) 2013-07-24
EP2151438A4 (en) 2010-09-08
RU2009147260A (ru) 2011-06-27
RU2449789C2 (ru) 2012-05-10
DK2151438T3 (da) 2012-11-26
CN101801941A (zh) 2010-08-11
ES2393424T3 (es) 2012-12-21
CA2687957C (en) 2014-11-25
CN101801941B (zh) 2012-12-12

Similar Documents

Publication Publication Date Title
WO2008143254A1 (ja) ＰＰＡＲδアゴニスト含有医薬
US8835435B2 (en) 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
RU2492167C2 (ru) Производные аминотриазола в качестве агонистов alх
ES2660571T3 (es) Inhibidores de la proteína tirosina fosfatasa humana y su uso farmacéutico
US6960605B2 (en) Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
NZ724602A (en) Ror-gamma modulators and uses thereof
EP1353676A1 (en) Method for treating fibrotic diseases or other indications
NZ592997A (en) Isoxazole derivatives for use as fungicides
CA2466140A1 (en) Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
CA2890554A1 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
CA2583217A1 (en) 1,3,4-thiadiazole compounds as protein kinase inhibitors
HK1111888A1 (en) Pharmaceutical preparation of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2- yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide n-[5-()-4--13--2-]-n--2-[4-(2-)]
CR20210686A (es) Análogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
RU2009133261A (ru) Комбинация антагониста мускаринового рецептора и агониста бета-2адренорецептора
MX2023001001A (es) Agonista del ppar-delta cristalino.
AU2020317374A1 (en) Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof
MX2021004457A (es) Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal.
JPWO2019151470A5 (ja)
US10537549B2 (en) Dihydroisoxazole compound for use in controlling sea lice
CN1615135A (zh) 磺酰胺前药如帕瑞考昔的口服剂型
JPWO2006118268A1 (ja) 慢性閉塞性肺疾患治療剤
RU2020124373A (ru) Профилактический агент и/или терапевтический агент для катаракты, медицинский состав для предотвращения и/или лечения катаракты, применение ppar-активатора для тех же целей и глазные капли
KR20040062961A (ko) 5-(4-(2-(ν-메틸-ν-(2-피리딜)아미도)에톡시)벤질)티아졸리딘-2,4-디온 및 그를 포함하는 제약 조성물
NO20080826L (no) 3-(2-(dimetylamino)metyl(cykloheks-1-yl))fenolmaleat og dets krystallinske former
WO2002053156A1 (en) Method for treating glaucoma ii b

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880025498.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08764395

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009515245

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2687957

Country of ref document: CA

Ref document number: MX/A/2009/012600

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008764395

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20097026251

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009147260

Country of ref document: RU

Ref document number: 7473/CHENP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12451564

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0811612

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091118